Posts

Showing posts from June, 2018

The Financial World: ZIM Laboratories Limited Listing on BSE Main Board

ZIM Laboratories Limited (ZIM) has been listed on the BSE Main Board on June 8, 2018. The book value price of ZIM was Rs 160 per equity share. Anwar Daud, Chairman & Managing Director, told media persons here recently that ZIM is amongst the few global companies to have developed and commercialized the oral film technology, besides also being the first Indian company to manufacture multi-layer thin films that contain more than one API on a single thin strip. Describing ZIM Laboratories as a unique R&D-centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS), he said ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines and the company listing on BSE on June 8 had a price discovery as per trading on the bourses. Original Article

APN News: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS).

Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries.

Original Article

Global Prime News: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology.


The first Indian company to manufacture multi-layer thin films - that contain more than one API on a single thin strip.Company to get listed on BSE Mainboard on June 08, 2018.The book value price of ZIM is Rs.160/- per equity share.ZIM got listed on OTC Exchange on India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses.

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS).

Original Article

NRI News 24x7: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology.The first Indian company to manufacture multi-layer thin films – that contain more than one API on a single thin strip.Company to get listed on BSE Mainboard on June 08, 2018.The book value price of ZIM is Rs. 160/-  per equity share ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS).

ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses.

Original Article

Malayalam Daily Press: Zim Laboratories to be listed on BSE tomorrow

Nagpur-based pharmaceuticals company Zim Laboratories will list on BSE on Friday, June 8.
Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015.

The company was recently by allowed SEBI to list on the main board of BSE.  This listing will provide an exit to some of its existing shareholders.

The book value of Zim Labs, promoted by Anwar Daud, is Rs 160 per equity share.
Daud and his family own 54 percent stake in the company, and private equity firm Ashmore Alchemy India Advisors owns around 22 percent. The rest is owned by minority shareholders.

Original Article

India Med Today: ZIM Laboratories Limited to List on BSE Main Board on June 8, 2018

ZIM Laboratories Limited (ZIM) – is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS).

ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses.

Promoted by Technocrat Dr. Anwar Daud, the company has a Unique R&D focused business model helping customers with product development, co-development, out licensing, manufacturing, supplies and marketing support with a strong IP base – 26 inventions with 53 patent filings and 174 clients across 45 countries.

Original Article

State Times: ZIM Laboratories Ltd to List on BSE on Friday

ZIM Laboratories (ZIM), an R&D centred pharmaceutical company today said it will list its shares on BSE on Friday.

ZIM got listed on OTC Exchange of India in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share.

Original Article

Latest Khabar: Zim Laboratories to be listed on BSE tomorrow

The company was allowed recently by SEBI to list on the BSE main board. This listing will provide an exit to existing shareholders.


Original Article

Newzicc: Zim Laboratories to be listed on BSE tomorrow

Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE. The book value of Zim Labs, promoted by Anwar Daud, is Rs 160 per equity share. Started in 1989, Zim clocked a profit after tax of Rs 18 crore on revenue of Rs 275 crore in FY18. Zim has developed and commercialised the complex oral film technology and plans to launch multi-layer thin films that contain more than one API on a single thin strip in coming months.

Original Article

Outlook India: ZIM Laboratories Ltd to List on BSE on Friday

ZIM Laboratories to List on BSE on Friday *ZIM Laboratories (ZIM), an R&D centered pharmaceutical company today said it will list its shares on BSE on Friday.

ZIM got listed on OTC Exchange of India in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share.

Original Article

Indian News and Times: ZIM Laboratories to get listed on BSE Mainboard on June 08, 2018

ZIM Laboratories to get listed on BSE Mainboard on June 08, 2018 at a book value price is Rs. 160/- per equity share

ZIM is amongst a few companies globally to have developed and commercialized the oral thin film technology.The first Indian company to manufacture multi layer thin films that contains more than one API on a single thin strip.

Company to get listed on BSE Mainboard on June 08, 2018.The book value price of ZIM is Rs.160/- per equity share. ZIM laboratories Limited (ZIM) - is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary Novel Drug Delivery Solutions (NDDS).

Original Article

BioSpectrum: ZIM Laboratories Ltd to list on BSE Main Board

ZIM is amongst a few companies globally to have developed and commercialized the oral film technology. The company is to get listed on BSE Mainboard on June 08, 2018. The book value price of ZIM is Rs. 160/- per equity share.


ZIM Laboratories Limited (ZIM) is a unique R&D centered pharmaceutical company focused on developing and supply of complex generics products based on proprietary  Novel Drug Delivery Solutions (NDDS). ZIM got listed on OTC Exchange of India in 1994, following the SEBI guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses.
Original Article

Chronicle Pharmabiz: Zim Laboratories to be listed on BSE tomorrow

Nagpur based Zim Laboratories Limited, a leading provider of new drug delivery systems, will be listing on Bombay Stock Exchange (BSE) Main Board on June 8 and will have a price discovery as per trading on the bourses. It is likely to fetch attractive returns for existing shareholders.

The book value price of Zim Labs, promoted by technocrate Dr Anwar Daud is Rs 160 per equity share. Daud and his family has 54 per cent stake in ZIM Labs and the private equity partner Ashmore Alchemy India Advisors has about 22 per cent. Rest is with minority shareholders.

Original Article

Express Pharma: Zim Laboratories eyes regulated markets

Nagpur-based Zim Laboratories will invest Rs 35 crores for setting up research lab and small manufacturing unit in Nagpur both for the regulated and Rest of the World (RoW) markets. Funds will be arranged from internal accrual and term loans. Both the new units are likely to be commissioned in next six months. On the sidelines of a press conference in Mumbai, Dr Anwar Daud, MD, Zim Laboratories said, “Our new research lab will specialise in complex generics and we will hire around 45-50 scientists. We will also set up a small batch manufacturing unit for high value and small volume formulation facility, which will be EU-GMP compliant.”
Original Article

Moneycontrol: Zim Laboratories to be listed on BSE tomorrow

Nagpur-based pharmaceuticals company Zim Laboratories will list on BSE on Friday, June 8.Zim Labs was trading on the OTC Exchange Of India before the Securities Exchange Board of India (SEBI) withdrew its recognition of it in March 2015. The company was recently by allowed SEBI to list on the main board of BSE.  This listing will provide an exit to some of its existing shareholders. Original Article

Business Standard: ZIM Laboratories to List on BSE on Friday

(ZIM), an R&D centredsaid it will list its shares on BSE on Friday. ZIM got listed on in 1994, following the Sebi guidelines the company will be listing on BSE and will have a price discovery as per trading on the bourses. The book value price is Rs 160 per equity share. Original Article

ZIMLab's Dr.Nidhi Sapkal delivered talk on "Technology development of Bi/Multilayer thin films" at International Conference on Pharmaceutical Development and Technology,Osaka, Japan.

Thin films are ideal dosage form for pediatric,generic,dysphagic,mentally challenged and bed ridden patients.These films are thin,flat,elegant,rectangular shaped dosage forms that can be delivered by either oral sublingual or buccal route.In the market, most of the available products are single layered and belong to category of orally dissolving films.A few belong to sublingual and buccal category.

Original Article